Radiation therapy for recurrent extrahepatic bile duct cancer.

<h4>Purpose</h4>More than half of patients with bile duct cancer (BDC) develop recurrence even after curative resection. Recurrent BDC has a poor prognosis, and no optimal treatment modality has been established. We therefore analyzed our experience on the survival outcomes of radiation...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Minji Koh, Jin-Hong Park, Changhoon Yoo, Sang Min Yoon, Jinhong Jung, Baek-Yeol Ryoo, Heung-Moon Chang, Kyu-Pyo Kim, Jae Ho Jeong, Jong Hoon Kim
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/adf727055ebf4848b8e36a20b3316af4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:adf727055ebf4848b8e36a20b3316af4
record_format	dspace
spelling	oai:doaj.org-article:adf727055ebf4848b8e36a20b3316af42021-12-02T20:10:33ZRadiation therapy for recurrent extrahepatic bile duct cancer.1932-620310.1371/journal.pone.0253285https://doaj.org/article/adf727055ebf4848b8e36a20b3316af42021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0253285https://doaj.org/toc/1932-6203<h4>Purpose</h4>More than half of patients with bile duct cancer (BDC) develop recurrence even after curative resection. Recurrent BDC has a poor prognosis, and no optimal treatment modality has been established. We therefore analyzed our experience on the survival outcomes of radiation therapy (RT) for recurrent extrahepatic bile duct cancer (EHBDC).<h4>Patients and methods</h4>We retrospectively analyzed the records of patients with recurrent EHBDC who underwent concurrent chemoradiation therapy (CCRT) or RT alone at our institution between January 2001 and June 2015. Freedom from locoregional progression (FFLP), progression-free survival (PFS), and overall survival (OS) were assessed, and univariate and multivariate analyses were performed to identify the prognostic factors.<h4>Results</h4>A total of 76 patients were included in the analysis. The median OS was 16 months and the rates of 2-year FFLP, PFS, and OS were 61%, 25%, and 33%, respectively. Among the evaluable patients, the first site of failure was the locoregional area in 16 patients, distant metastasis in 27, and both sites in 8. On univariate analysis, disease-free interval (p = 0.012) and concurrent chemotherapy (p = 0.040) were found as significant prognostic factors for OS. One patient with CCRT developed a grade 3 hematologic toxicity, and two patients experienced late grade 3 toxicities including duodenal ulcer bleeding and obstruction.<h4>Conclusions</h4>RT for recurrent EHBDC showed favorable survival and local control with limited treatment-related toxicities. Considering that the most common pattern of failure was distant metastasis, further studies on the optimal scheme of chemotherapy and RT are warranted.Minji KohJin-Hong ParkChanghoon YooSang Min YoonJinhong JungBaek-Yeol RyooHeung-Moon ChangKyu-Pyo KimJae Ho JeongJong Hoon KimPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 6, p e0253285 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Minji Koh Jin-Hong Park Changhoon Yoo Sang Min Yoon Jinhong Jung Baek-Yeol Ryoo Heung-Moon Chang Kyu-Pyo Kim Jae Ho Jeong Jong Hoon Kim Radiation therapy for recurrent extrahepatic bile duct cancer.
description	<h4>Purpose</h4>More than half of patients with bile duct cancer (BDC) develop recurrence even after curative resection. Recurrent BDC has a poor prognosis, and no optimal treatment modality has been established. We therefore analyzed our experience on the survival outcomes of radiation therapy (RT) for recurrent extrahepatic bile duct cancer (EHBDC).<h4>Patients and methods</h4>We retrospectively analyzed the records of patients with recurrent EHBDC who underwent concurrent chemoradiation therapy (CCRT) or RT alone at our institution between January 2001 and June 2015. Freedom from locoregional progression (FFLP), progression-free survival (PFS), and overall survival (OS) were assessed, and univariate and multivariate analyses were performed to identify the prognostic factors.<h4>Results</h4>A total of 76 patients were included in the analysis. The median OS was 16 months and the rates of 2-year FFLP, PFS, and OS were 61%, 25%, and 33%, respectively. Among the evaluable patients, the first site of failure was the locoregional area in 16 patients, distant metastasis in 27, and both sites in 8. On univariate analysis, disease-free interval (p = 0.012) and concurrent chemotherapy (p = 0.040) were found as significant prognostic factors for OS. One patient with CCRT developed a grade 3 hematologic toxicity, and two patients experienced late grade 3 toxicities including duodenal ulcer bleeding and obstruction.<h4>Conclusions</h4>RT for recurrent EHBDC showed favorable survival and local control with limited treatment-related toxicities. Considering that the most common pattern of failure was distant metastasis, further studies on the optimal scheme of chemotherapy and RT are warranted.
format	article
author	Minji Koh Jin-Hong Park Changhoon Yoo Sang Min Yoon Jinhong Jung Baek-Yeol Ryoo Heung-Moon Chang Kyu-Pyo Kim Jae Ho Jeong Jong Hoon Kim
author_facet	Minji Koh Jin-Hong Park Changhoon Yoo Sang Min Yoon Jinhong Jung Baek-Yeol Ryoo Heung-Moon Chang Kyu-Pyo Kim Jae Ho Jeong Jong Hoon Kim
author_sort	Minji Koh
title	Radiation therapy for recurrent extrahepatic bile duct cancer.
title_short	Radiation therapy for recurrent extrahepatic bile duct cancer.
title_full	Radiation therapy for recurrent extrahepatic bile duct cancer.
title_fullStr	Radiation therapy for recurrent extrahepatic bile duct cancer.
title_full_unstemmed	Radiation therapy for recurrent extrahepatic bile duct cancer.
title_sort	radiation therapy for recurrent extrahepatic bile duct cancer.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/adf727055ebf4848b8e36a20b3316af4
work_keys_str_mv	AT minjikoh radiationtherapyforrecurrentextrahepaticbileductcancer AT jinhongpark radiationtherapyforrecurrentextrahepaticbileductcancer AT changhoonyoo radiationtherapyforrecurrentextrahepaticbileductcancer AT sangminyoon radiationtherapyforrecurrentextrahepaticbileductcancer AT jinhongjung radiationtherapyforrecurrentextrahepaticbileductcancer AT baekyeolryoo radiationtherapyforrecurrentextrahepaticbileductcancer AT heungmoonchang radiationtherapyforrecurrentextrahepaticbileductcancer AT kyupyokim radiationtherapyforrecurrentextrahepaticbileductcancer AT jaehojeong radiationtherapyforrecurrentextrahepaticbileductcancer AT jonghoonkim radiationtherapyforrecurrentextrahepaticbileductcancer
_version_	1718375019077173248

Radiation therapy for recurrent extrahepatic bile duct cancer.

Ejemplares similares